SOF/VEL/VOX Results in High SVR12 Rates when Administered for 12 Weeks in Daa-Experienced Patients or for 8 Weeks in Daa-Naïve Patients: An Integrated Analysis of the POLARIS-1, POLARIS-2, POLARIS-3 and POLARIS-4 Studies
Sign Up to like & getrecommendations! Published in 2017 at "Gastroenterology"
DOI: 10.1016/s0016-5085(17)33572-2
Abstract: Background The once-daily fixed-dose combination tablet of sofosbuvir/velpatasvir/voxilaprevir(SOF/VEL/VOX) was evaluated for the treatment of genotype 1–6 HCV infection in four Phase 3 studies in direct-acting antiviral (DAA)-experienced (POLARIS-1 and POLARIS-4) and DAA-naive (POLARIS-2 and POLARIS-3)… read more here.
Keywords: polaris polaris; sof vel; weeks daa; polaris ... See more keywords
Real‐world effectiveness of sofosbuvir/velpatasvir/voxilaprevir in 573 direct‐acting antiviral experienced hepatitis C patients
Sign Up to like & getrecommendations! Published in 2019 at "Journal of Viral Hepatitis"
DOI: 10.1111/jvh.13115
Abstract: Sofosbuvir/velpatasvir/voxilaprevir (SOF/VEL/VOX) provides a needed hepatitis C virus (HCV) antiviral option for direct‐acting antiviral (DAA)‐experienced patients. We evaluated the effectiveness of SOF/VEL/VOX for 12 weeks in DAA‐experienced patients with genotype 1‐4 treated in clinical practice.… read more here.
Keywords: sof vel; vel vox; svr rates;
Real world SOF/VEL/VOX retreatment outcomes and viral resistance analysis for HCV patients with prior failure to DAA therapy
Sign Up to like & getrecommendations! Published in 2021 at "Journal of Viral Hepatitis"
DOI: 10.1111/jvh.13549
Abstract: Sustained viral response (SVR) rates for direct‐acting antiviral (DAA) therapy for hepatitis C virus (HCV) infection routinely exceed 95%. However, a small number of patients require retreatment. Sofosbuvir, velpatasvir and voxilaprevir (SOF/VEL/VOX) is a potent… read more here.
Keywords: vel; retreatment; sof vel; daa ... See more keywords